Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia

a subanalysis of the DASISION 5-year final report

Hirohisa Nakamae, Shin Fujisawa, Michinori Ogura, Toshiki Uchida, Yasushi Onishi, Masafumi Taniwaki, Atae Utsunomiya, Kosei Matsue, Yasushi Takamatsu, Kensuke Usuki, Mitsune Tanimoto, Yoji Ishida, Kazuteru Ohashi, Li Li, Masafumi Miyoshi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The international phase III DASISION trial demonstrated improved efficacy of dasatinib versus imatinib in treatment-naive patients with chronic myeloid leukemia in the chronic phase (CML-CP). We report efficacy and safety outcomes in a Japanese population from the final, 5-year follow-up of DASISION. At the end of the study, 77% (20/26) of dasatinib-treated and 61% (14/23) of imatinib-treated patients remained on initial therapy. Improved responses were observed in Japanese patients who received dasatinib versus imatinib (complete cytogenetic response: 96 vs 87%; major molecular response: 88 vs 74%; BCR-ABL1 ≤0.0032% International Scale [MR4.5]: 58 vs 52%). In patients who achieved BCR-ABL1 ≤10% at 3 months, 5-year progression-free survival and overall survival rates were high with dasatinib (96 and 96%) and imatinib (88 and 100%). The majority of adverse events were grade 1/2 in Japanese patients. Pleural effusion occurred more frequently in dasatinib-treated Japanese patients versus all patients (42 vs 28%), with no treatment discontinuations. Overall, in Japanese patients, dasatinib maintained its safety profile and had higher or comparable response and survival outcomes compared with imatinib or with all patients in DASISION. These findings demonstrate the long-term efficacy and tolerability of dasatinib and support frontline treatment of Japanese patients with CML-CP with dasatinib.

Original languageEnglish
Pages (from-to)792-804
Number of pages13
JournalInternational Journal of Hematology
Volume105
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Leukemia, Myeloid, Chronic Phase
Imatinib Mesylate
Dasatinib
Safety
Pleural Effusion
Therapeutics
Cytogenetics
Disease-Free Survival
Survival Rate

Keywords

  • CML
  • Dasatinib
  • Imatinib
  • Japan
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia : a subanalysis of the DASISION 5-year final report. / Nakamae, Hirohisa; Fujisawa, Shin; Ogura, Michinori; Uchida, Toshiki; Onishi, Yasushi; Taniwaki, Masafumi; Utsunomiya, Atae; Matsue, Kosei; Takamatsu, Yasushi; Usuki, Kensuke; Tanimoto, Mitsune; Ishida, Yoji; Ohashi, Kazuteru; Li, Li; Miyoshi, Masafumi.

In: International Journal of Hematology, Vol. 105, No. 6, 01.06.2017, p. 792-804.

Research output: Contribution to journalArticle

Nakamae, H, Fujisawa, S, Ogura, M, Uchida, T, Onishi, Y, Taniwaki, M, Utsunomiya, A, Matsue, K, Takamatsu, Y, Usuki, K, Tanimoto, M, Ishida, Y, Ohashi, K, Li, L & Miyoshi, M 2017, 'Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report', International Journal of Hematology, vol. 105, no. 6, pp. 792-804. https://doi.org/10.1007/s12185-017-2208-2
Nakamae, Hirohisa ; Fujisawa, Shin ; Ogura, Michinori ; Uchida, Toshiki ; Onishi, Yasushi ; Taniwaki, Masafumi ; Utsunomiya, Atae ; Matsue, Kosei ; Takamatsu, Yasushi ; Usuki, Kensuke ; Tanimoto, Mitsune ; Ishida, Yoji ; Ohashi, Kazuteru ; Li, Li ; Miyoshi, Masafumi. / Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia : a subanalysis of the DASISION 5-year final report. In: International Journal of Hematology. 2017 ; Vol. 105, No. 6. pp. 792-804.
@article{01fe5a4aa5244bf9bba1e40336e0b7aa,
title = "Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report",
abstract = "The international phase III DASISION trial demonstrated improved efficacy of dasatinib versus imatinib in treatment-naive patients with chronic myeloid leukemia in the chronic phase (CML-CP). We report efficacy and safety outcomes in a Japanese population from the final, 5-year follow-up of DASISION. At the end of the study, 77{\%} (20/26) of dasatinib-treated and 61{\%} (14/23) of imatinib-treated patients remained on initial therapy. Improved responses were observed in Japanese patients who received dasatinib versus imatinib (complete cytogenetic response: 96 vs 87{\%}; major molecular response: 88 vs 74{\%}; BCR-ABL1 ≤0.0032{\%} International Scale [MR4.5]: 58 vs 52{\%}). In patients who achieved BCR-ABL1 ≤10{\%} at 3 months, 5-year progression-free survival and overall survival rates were high with dasatinib (96 and 96{\%}) and imatinib (88 and 100{\%}). The majority of adverse events were grade 1/2 in Japanese patients. Pleural effusion occurred more frequently in dasatinib-treated Japanese patients versus all patients (42 vs 28{\%}), with no treatment discontinuations. Overall, in Japanese patients, dasatinib maintained its safety profile and had higher or comparable response and survival outcomes compared with imatinib or with all patients in DASISION. These findings demonstrate the long-term efficacy and tolerability of dasatinib and support frontline treatment of Japanese patients with CML-CP with dasatinib.",
keywords = "CML, Dasatinib, Imatinib, Japan, Tyrosine kinase inhibitor",
author = "Hirohisa Nakamae and Shin Fujisawa and Michinori Ogura and Toshiki Uchida and Yasushi Onishi and Masafumi Taniwaki and Atae Utsunomiya and Kosei Matsue and Yasushi Takamatsu and Kensuke Usuki and Mitsune Tanimoto and Yoji Ishida and Kazuteru Ohashi and Li Li and Masafumi Miyoshi",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s12185-017-2208-2",
language = "English",
volume = "105",
pages = "792--804",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia

T2 - a subanalysis of the DASISION 5-year final report

AU - Nakamae, Hirohisa

AU - Fujisawa, Shin

AU - Ogura, Michinori

AU - Uchida, Toshiki

AU - Onishi, Yasushi

AU - Taniwaki, Masafumi

AU - Utsunomiya, Atae

AU - Matsue, Kosei

AU - Takamatsu, Yasushi

AU - Usuki, Kensuke

AU - Tanimoto, Mitsune

AU - Ishida, Yoji

AU - Ohashi, Kazuteru

AU - Li, Li

AU - Miyoshi, Masafumi

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The international phase III DASISION trial demonstrated improved efficacy of dasatinib versus imatinib in treatment-naive patients with chronic myeloid leukemia in the chronic phase (CML-CP). We report efficacy and safety outcomes in a Japanese population from the final, 5-year follow-up of DASISION. At the end of the study, 77% (20/26) of dasatinib-treated and 61% (14/23) of imatinib-treated patients remained on initial therapy. Improved responses were observed in Japanese patients who received dasatinib versus imatinib (complete cytogenetic response: 96 vs 87%; major molecular response: 88 vs 74%; BCR-ABL1 ≤0.0032% International Scale [MR4.5]: 58 vs 52%). In patients who achieved BCR-ABL1 ≤10% at 3 months, 5-year progression-free survival and overall survival rates were high with dasatinib (96 and 96%) and imatinib (88 and 100%). The majority of adverse events were grade 1/2 in Japanese patients. Pleural effusion occurred more frequently in dasatinib-treated Japanese patients versus all patients (42 vs 28%), with no treatment discontinuations. Overall, in Japanese patients, dasatinib maintained its safety profile and had higher or comparable response and survival outcomes compared with imatinib or with all patients in DASISION. These findings demonstrate the long-term efficacy and tolerability of dasatinib and support frontline treatment of Japanese patients with CML-CP with dasatinib.

AB - The international phase III DASISION trial demonstrated improved efficacy of dasatinib versus imatinib in treatment-naive patients with chronic myeloid leukemia in the chronic phase (CML-CP). We report efficacy and safety outcomes in a Japanese population from the final, 5-year follow-up of DASISION. At the end of the study, 77% (20/26) of dasatinib-treated and 61% (14/23) of imatinib-treated patients remained on initial therapy. Improved responses were observed in Japanese patients who received dasatinib versus imatinib (complete cytogenetic response: 96 vs 87%; major molecular response: 88 vs 74%; BCR-ABL1 ≤0.0032% International Scale [MR4.5]: 58 vs 52%). In patients who achieved BCR-ABL1 ≤10% at 3 months, 5-year progression-free survival and overall survival rates were high with dasatinib (96 and 96%) and imatinib (88 and 100%). The majority of adverse events were grade 1/2 in Japanese patients. Pleural effusion occurred more frequently in dasatinib-treated Japanese patients versus all patients (42 vs 28%), with no treatment discontinuations. Overall, in Japanese patients, dasatinib maintained its safety profile and had higher or comparable response and survival outcomes compared with imatinib or with all patients in DASISION. These findings demonstrate the long-term efficacy and tolerability of dasatinib and support frontline treatment of Japanese patients with CML-CP with dasatinib.

KW - CML

KW - Dasatinib

KW - Imatinib

KW - Japan

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85016185415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016185415&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2208-2

DO - 10.1007/s12185-017-2208-2

M3 - Article

VL - 105

SP - 792

EP - 804

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 6

ER -